Lexeo Therapeutics, Inc.
LXEO
$4.76
$0.827721.06%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 18.37M | 23.42M | 16.56M | 15.74M | 8.21M |
| Gross Profit | -18.37M | -23.42M | -16.56M | -15.74M | -8.21M |
| SG&A Expenses | 9.02M | 8.12M | 6.99M | 7.55M | 6.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.38M | 31.54M | 23.55M | 23.29M | 14.97M |
| Operating Income | -27.38M | -31.54M | -23.55M | -23.29M | -14.97M |
| Income Before Tax | -25.92M | -29.49M | -21.24M | -21.68M | -14.19M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.92M | -29.49M | -21.24M | -21.68M | -14.19M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.92M | -29.49M | -21.24M | -21.68M | -14.19M |
| EBIT | -27.38M | -31.54M | -23.55M | -23.29M | -14.97M |
| EBITDA | -27.23M | -31.38M | -23.39M | -23.14M | -14.82M |
| EPS Basic | -0.78 | -0.89 | -0.64 | -0.77 | -0.86 |
| Normalized Basic EPS | -0.49 | -0.56 | -0.40 | -0.48 | -0.54 |
| EPS Diluted | -0.78 | -0.89 | -0.64 | -0.77 | -0.86 |
| Normalized Diluted EPS | -0.49 | -0.56 | -0.40 | -0.48 | -0.54 |
| Average Basic Shares Outstanding | 33.08M | 33.06M | 33.00M | 27.98M | 16.44M |
| Average Diluted Shares Outstanding | 33.08M | 33.06M | 33.00M | 27.98M | 16.44M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |